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Summary The biological property of an antibody is determined by its antigen binding characteristics and its
isotype-related effector functions. We have established monoclonal antibodies of different isotypes by stepwise
selection and cloning of the hybridoma CE7. The original CE7 secretes an IgGI/c (CE7yl) antibody that
recognises a 185 kD cell surface glycoprotein expressed on all human sympatho-adrenomedullary cells.
Isotype-switch variants were isolated in the following sequence: from the original CE7yl, CE7y2b variants
were isolated, and from a CE772b variant CE7y2a variants were isolated. The antibodies of three different
isotype variant cell lines possess identical antigen binding characteristics, but display distinct effector functions
as demonstrated by antibody dependent cell-mediated cytotoxicity (ADCC). ADCC was performed with the
neuroblastoma line IMR-32 as the target cells, and different FcRy positive cells were either freshly isolated
from human peripheral blood leukocytes or cultured for 6-10 days and tested as potential effector cells.
Tumour lysis mediated by monocyte-derived macrophages depended on the presence of CE7y2a antibodies;
antibodies from the CE7 hybridomas of y2b and y1 isotypes were virtually inactive in ADCC assay.
Pre-exposure of macrophages to rIFN-y enhanced their ADCC activity, a result that is compatible with the
notion that the high affinity Fc IgG receptor (FcRyI/CD64) is involved in the triggering of ADCC in
macrophages. In contrast to macrophages, mononuclear cells, nonadherent cells and monocytes displayed
considerable non-specific lytic activity, which was little influenced by the presence of antibody regardless of the
isotype added.
Human neuroblastomas can arise either during embryo-
genesis or post-natally from stem cells of the peripheral
sympathetic nervous system. These tumours represent highly
malignant solid neoplasms. They show various stages of
development which are reflected by particular molecular
structures on the cell surface (Hughes et al., 1974; Evans et
al., 1976; Momoi et al., 1980). The phenotype of neuroblas-
toma can be identified using a panel of monoclonal anti-
bodies (MAb) specific for various cell surface molecules
expressed at different stages of development (Kemshead &
Black, 1980; Kemshead et al., 1983; Schonmann et al., 1986).
The monoclonal antibody CE7 possesses so far a unique
specificity in that it recognises a glycoprotein of 185 kD
particularly expressed on the surface of all neuroblastoma
cells independently of their histological grade, and other
neoplastically transformed sympatho-adreno-medullary cells.
CE7 does not bind to cells or tumours of non-neuroecto-
dermal origin. Since no reactivity toward hemopoietic cells
has been observed, this MAb might be used to remove
tumour cells from the bone marrow. Up to now it has been
used for tumour diagnosis (Sch6nmann et al., 1986) and for
in vivo localisation of the tumour (Rentsch et al., 1988).
From the original CE7-yl/c secreting hybridoma, isotype vari-
ants were selected which bind to the same epitope as the
original CE7 and show the same N-terminal amino-acid
sequence. Their functionally rearranged variable H and L
chain gene segments represent the same V region rearrange-
ments, but they use different H chain genes. For example,
isotype switch variants of CE7 have been obtained that
produces antibodies exhibiting complement-mediated lysis of
neuroblastoma cells, whereas antibodies of the original CE7
hybridoma are virtually inactive in this regard (d'Uscio et al.,
in preparation).
The purpose of this study was to select isotype switch
variants that produce antibodies which supported antibody-
dependent cell-mediated cytotoxicity (ADCC), an effector
function believed to be involved in the elimination of anti-
body-coated tumour cells (Pearson, 1978; Hellstrom et al.,
1981; Imai et al., 1982), and to test various Fc IgG receptor
(FcyR) positive cells for their capacity to mediate ADCC
using the antibodies of the selected variants. FcRT positive
cell types reported to have ADCC activity include cells of the
monocyte/macrophage series (Katz et al., 1980; Ralph et al.,
1980), some granulocytes (Conkling et al., 1982) and cells
belonging to the NK/K cell lineage (de Lanzaduri et al.,
1979). We report here that monoclonal CE7y2a antibodies
trigger macrophage ADCC, while CE7y2b and CE771 anti-
bodies were ineffective. Only macrophages exhibited ADCC
activity with the antibodies tested; other types ofFcR?y cells
tested were inactive as ADCC mediators. This is consistent
with the hypothesis that mainly high-affinity FcRyI (CD64)
are involved in CE7-mediated cellular cytotoxicity of neuro-
blastoma cells.
Materials and methods
Animals andmaterials
Female Balb/c mice aged 6-8 weeks were obtained from the
CIBA-GEIGY animal breeding farm (Basel, Switzerland).
Cell media were bought from Seromed (Munich, Germany)
and Gibco (Paisley, Scotland). Alkaline phosphatase- and
P-galactosidase-labelled goat anti-mouse isotypes were
obtained from Southern Biotechnology Associates, Inc. (SBA,
Birmingham, AL). Unlabelled goat anti-mouse Ig isotype
specific reagents were obtained from Meloy (Springfield,
VA). 5"Cr-sodium chromate (5 mCi ml-') was purchased
from Ire-Celltarg (Fleurus, Belgium). Recombinant
interferon-y (rIFN-y) was kindly provided by Biogen
(Geneva, Switzerland); its specific activity was
1.3 x 107 U mg-' as assessed by Biogen with EMC virus and
WISH cells. The lyophilised material, containing more than
99% rIFN-y, salts and human serum albumin was dissolved
in PBS, at a concentration of 5 x 1O U ml-', and used
within 4 weeks. Monoclonal anti-arsonate antibody of y2a
isotype was kindly provided by Dr S.S. Alkan, CIBA-
GEIGY, Ltd (Basel, Switzerland). MAb were purified from
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ascites fluid in a single step procedure by a programmable
HPLC linear gradient system, fitted with Bakerbond MAb
and Bakerbond ABx Gold analytical columns (Baker, Phil-
lipsburg, NJ) according to the manufacturers recommenda-
tions. For Scatchard plot analysis, purified monomeric
CE7'1 was labelled with "25I at the Paul Scherrer Institute
(Villigen, Switzerland) by the method of Bolton-Hunter. The
specific activity was 0.5 x I03 c.p.m. ng-' CE7y1. Labelled
CE7'y1 (400 gml-') was stored at 4°C and used within 1
week. All other chemicals were obtained from Fluka AG
(Buchs, Switzerland), Merck (Darmstadt, Germany) or Sigma
(St Louis, MO).
Cell lines
The establishment of the CE7y1 hybridoma line has been
described by Sch6nmann et al. (1986). It had been produced
by fusion of spleen cells from Balb/c mice immunised with
IMR-32 human neuroblastoma cells, with P3Ul mouse mye-
loma cells. The latter is a kappa L chain producer, non
secretor line (Schonmann et al., 1986). The hybridoma cells
were grown for 3 months in RPMI-1640 medium supplement-
ed with 10% FCS (Seromed or Biological Industries, Kibbutz
Beth Haemek, Israel), 10-3 M sodium pyruvate, 5.6 x 10-6 M
folic acid, 2 x 10- M glutamine, 200 IU ml-' penicillin and
200jLg ml-' streptomycin. The human neuroblastoma cell
lines SK-N-AS and SK-N-MC were kindly provided by Dr
L. Helson, Memorial Sloan Kettering Cancer Center (New
York, NY) and IMR-32 was obtained from the American
Tissue Type Collection, Washington. The human neuroblas-
toma cells were maintained in Eagle's minimal essential
medium (EMEM) buffered with sodium bicarbonate and
supplemented with 10% heat inactivated (30min, 56°C) FCS
(Gibco), 2 x10-3M glutamine, 50 IU ml-' penicillin, 50 tg
ml-' streptomycin and 1% non-essential amino acids (com-
plete medium). Neuroblastoma cultures were split at a ratio
of 1:4 at approximately weekly intervals. All cell lines were
maintained at 37°C in a 5% CO2 incubator.
Identification andselection ofisotype switch variants
hydridomas
The identification of switch-variants was achieved by analysis
of culture supernatants using an isotype-specific sandwich
ELISA. Briefly, 96-well polystyrene microtitre plates
(NUNC, Roskilde, Denmark, Typ I 4-39454) were coated
with 0.5pg of goat anti-mouse isotype-specific reagent in
100jil PBS pH 8.0 by overnight incubation at room tempera-
ture. The plates were washed with PBS containing 0.20%
Tween 20 and 0.02% NaN3. Remaining free binding sites
were blocked by incubation for 30 min at 37°C with a 1%
casein hydrolysate (Oxoid Ltd., Basingstoke, UK) solution
made with PBS containing 5% Tween 20 and 0.2% NaN3.
The culture supernatants (100 gLl) were added to the coated
plates, and incubated for 2 h at 37°C. Alkaline phosphatase-
labelled goat anti-mouse isotype was then added in 100fsl
PBS/1% casein hydrolysate/5% Tween 20/0.02% NaN3.
After 2h at 37°C, p-nitrophenylphosphate (1.5mgml-') in
1 M diethanolamine pH 9.8/0.01% MgCl2/0.02% NaN3 was
added and the absorbance was measured after 30-60 min at
37°C in an automated Titertek Multiscan MC ELISA reader
(Flow, Irvine, Scotland).
Neuroblastoma-binding ofCE7 antibodies
The neuroblastoma reactivity of CE7 isotype variants was
tested by a cell-ELISA (Feit et al., 1983). That is, V-
bottomed PVC microtitre plates (Dynatech, Kloten, Switzer-
land) were preincubated with PBS/i % BSA/l.5 mM MgCl2/
2 mM P-mercaptoethanol (PBS-BSA) for 30 min at 37C.
Viable, exponentially growing neurobastoma cells were
harvested in Puck's A buffer (Reynolds & Maples, 1985),
sonicated for 1-2 s to dissociate clumps and counted in a
haemocytometer. Binding studies of CE7 antibody were per-
formed by using 7.5 x 105 neuroblastoma cells/well. After 2 h
at 4°C the plates were centrifuged at 200g for 5 min and the
cells resuspenced in one drop of PBS-BSA. After two wash-
ings, with 150fil PBS-BSA, P-galactosidase-labelled goat
anti-mouse isotype-specific antibody was added in 100 ,l
PBS-BSA and the plates were incubated overnight at 4°C.
Then after four washings, o-nitro-phenyl-p-D-galactopyrano-
side (1 mgml-') in PBS/i1.5 mM MgCl2/100mM P-mercapto-
ethanol was added and the plates were incubated for
60-90 min at 37°C. The reaction was stopped with 0.5 M
sodium carbonate and the absorbance was measured in a
Titertek Multiscan MC ELISA reader.
Effectorcellpreparation
Peripheral blood mononuclear cells (PBMC) were isolated
from buffy coats of450 ml blood samples by isopycnic centri-
fugation over Ficoll-Hypaque.
Nonadherent lymphocytes (T cells and NK/K cells) were
isolated from PBMC by nylon-wool fractionation (Julius et
al., 1973). PBMC (50-100 x 106) were loaded onto a 0.6g
nylon wool column (Fenwal, Deerfield, IL). After 1 h of
incubation at 37°C, nonadherent cells were eluted with
EMEM containing 2.5% HEPES, 5% FCS at pH 7.3, wash-
ed with PBS and resuspended in complete medium.
Monocytes were purified by elutriation-centrifugation
(Clemetson et al., 1985) in a Beckman J2-21 M centrifuge
fitted with a J-6B rotor and a Beckman type elutriation
chamber. The flow rate was held constant at 17.3 mlmin-'
by gradual reduction of the rotation speed. The monocyte-
enriched fractions were pooled, washed and resuspended in
complete medium; they contained 95-99% monocytes.
Macrophages were derived from monocytes as described
by Jungi and Hafner (1986). PBMC were incubated for 1 h in
tissue culture flasks containing RPMI-1640 supplemented
with HEPES (25 mM) and 2% heat inactivated homologous
human serum (ABRh-). Nonadherent cells were removed by
rinsing, and adherent cells were cultured overnight in
medium containing 10% serum. Then, adherent cells were
dislodged by vortexing, washed with PBS, and resuspended
in medium supplemented with 15% serum (5 x 105 adherent
cellsml-'). The cells, now consisting mainly of monocytes
(;90%) were placed in sealed bags made from hydrophobic
teflon foil (DuPont de Nemours). After 1 week, monocytes
had differentiated to macrophages as evidenced by an in-
crease in size, enhanced phagocytosis capacity, loss of
myeloperoxidase and other functional alterations (Andreesen
et al., 1983; Jungi & Hafner, 1986; Jungi & Peterhans, 1988).
These cells were harvested between day 7 and 9 from the
bags, washed with PBS and resuspended in ADCC medium.
In some experiments, macrophages were exposed for the last
2 days ofculture to rIFN-y (500 U ml-'). This dose had been
found to be optimal with respect to several activation para-
meters (Jungi et al., 1989). In particular, it was shown to
increase the number of high-affinity FcRIyI/CD64, but not of
low-affinity FcRyII/CD32 or FcRyIII/CD16 (Jungi & Peter-
hans, 1988).
Target cellpreparation
Viable, exponentially growing IMR-32 neuroblastoma cells
were harvested in Puck's A buffer supplemented with 1 mM
EDTA and 10 mM HEPES (Reynolds & Maples, 1985). After
5 min centrifugation at 200g and two washings with com-
plete medium, the cells were sonicated for 1-2 s to disperse
clumps and counted in a haemocytometer. Cells (5 x 106)
were labelled with 50JACi 5"Cr sodium chromate (specific
activity 600-900 mCi mg-L Cr) in 150 ul heat inactivated
FCS for 1 h at 37°C in 5% CO2. The labelling culture was
gently shaken every 15 min. After four washings the cells
were resuspended at the density required for ADCC assay.
Determination ofantibody-dependent cellular cytotoxicity
ADCC was assayed in V-bottomed PVC microtitre plates
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bated with complete medium for 1 h at 37°C. In some
experiments round-bottomed polystyrene microtitre plates
(Greiner, Niirtingen, Germany) were also used. To each well
was added 50jLl aliquots containing 2.5 x 103 51Cr labelled
IMR-32 target cells in complete medium followed by 501l
purified CE7'1, CE7y2a, CE77y2b or control (anti-arsonate)
72a antibodies. Possible aggregates of MAbs were removed
by centrifugation in an Eppendorf centrifuge. The cells were
incubated with antibodies for 30min at room temperature
before adding 100IlI of effector cells diluted in complete
medium to give the specified effector/target (E/T) ratio. The
plates were centrifuged (5 min, 200 g) and placed in a 37°C/
5% CO2 incubator. After 1 to 18 h, the plates were centri-
fuged for 5 min at 200 g and100iLl samples were taken from
each well and transferred to plastic tubes. The release of5'Cr
was measured in a Kontron MR 480 automatic gamma
counting system. Control wells containing labelled IMR-32
and either antibody or effector cells alone were included in
each assay. The specific release was expressed by the formula:
[c.p.m. experimental release - c.p.m. spontaneous release]/
[c.p.m. input - c.p.m. spontaneous release] x 100. All assays
were set up twice in triplicate.
Results
Isolation ofswitch variants
The parent hybridoma cell line CE7 producingyl/x antibody
had been growing in culture for more than 3 months and the
selected CE7'y2b hybridoma for1 month without subcloning.
The isolation ofy2b and '2a variants was made by sequential
subculturing. The original CE771 was subcultured to obtain
72b and then 72b was subcultured to obtainy2a, as originally
described by Muller and Rajewsky (1983).
In a first round of selection, starting with 1.5 x106 CE7'y1
cells at a density of 3,000 cells/well, 48'y2b positive wells
were obtained. The variants were identified by sandwich
ELISA using two polyclonal isotype-specific antibodies.
Selected positive cultures were subjected to a second round of
enrichment at a density of 50 cells/well. The cultures produc-
ing the relevant isotype were cloned three times by limiting
dilution. By using the same procedure 30 'j2a positive wells
were detected from 1.5 x 106 cells of a selected CE7-y2b clone.
For both isotypes, selected variants were obtained at a fre-
quency of 1 to 2 x 10-'. The cloned switch variants were
further selected for their reactivity with neuroblastoma cells
using a cell ELISA with viable IMR-32 cells and polyclonal
isotype-specific P-galactosidose labelled antibodies. From the
11 selected y2b secreting CE7 clones, three bound to IMR-32,
SK-N-AS and SK-N-MC and from seven selected v2a clones,
five bound to these neuroblastomas lines. The three CE7y2b
variants secreted only the y2b isotype, whereas clones which
exclusively secreted 72a antibodies could not be found. All
five CE7y2a secreting clones expressed both '2a andy2b
isotypes after three additional subclonings. As demonstrated
by surface staining with FITC labelled antibodies more than
99% of cells in all cultures were double producers. The
composition of the antibodies secreted by a CE7y2a positive
clone after purification was 55% y2a and 45% 72b. The 72a
antibody was separated from 72b by HPLC using Bakerbond
columns (d'Uscio et al., in preparation).
The biochemical and molecular genetic properties of three
CE7 isotype variants were extensively studied and published
separately (d'Uscio et al., in preparation). The antibodies use
identical VH and VL gene segments but distinct CH. The H
chains are N-terminally blocked and the L chains were iden-
tical in their FRI region but different to the P3Ul line.
Binding capacity and characteristics ofmonomeric CE7"1
All CE7 antibodies, regardless of their isotype, bound to
IMR-32 cells as demonstrated in a cell-ELISA using poly-
clonal isotype-specific labelled antibodies (Figure 1). The
titration of CE7 antibodies against a constant number of
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Figure la Binding of CE7yl (A-A), y2a (U-U) andy2b
(@-@) to IMR-32 cells. Bound antibodies were measured with
isotype-specific P-galactosidase-labelled goat anti-mouse anti-
bodies in ELISA. The data represent mean value of triplicate.
Deviations were <15%. b, Inhibition of CE7y1 binding by
CE7y2a and CE7y2b in an IMR-32 neuroblastoma cell-ELISA.
The cells were incubated with dilutions of CE7y2a or CE7y2b and
a constant amount ofCE7My1. BoundCE7M1 was measured with P-galactosidase-labelled goat anti-mouse y1 specific antibody,
(U-U) CE7yl inhibition by CE7y2a. (0 0) CE7y1 inhibition
byCE7y2b.
IMR-32 cells resulted in similar binding curves for all iso-
types. Also the binding to the neuroblastoma linesSK-N-AS
and SK-N-MC was the same for all isotypes (data not
shown). As shown in Figure lb, by competitive ELISA
inhibition, the CE7y2a and CE7y2b antibodies recognize the
same epitope as the original CE7y1 antibody and display the
same affinity for the neuroblastoma cells.
The cell binding capacity of CE7 antibodies was deter-
mined by incubating a constant number of IMR-32 cells with
varying amounts of purified, monomeric251I-CE7y1; the Scat-
chard plot (not shown) was linear with r equal to 0.92. The
IMR-32 cells expressed 120,000 binding sites, and the dissoc-
iation constant (Kd) of the CE7 antibodies was 1.44 x 107 M-1.
The influence ofeffector and target cell type
In preliminary tests, the rates of cell death (spontaneous
lysis) of neuroblastoma lines IMR-32, SK-N-AS and SK-N-
MC were measured over an 18 h period. The rates of cell
death for the three neuroblastomas decreased in the order of:
SK-N-MC; SK-N-AS; IMR-32. Based on these results IMR-
32 was selected as the target cell for ADCC experiments.
IMR-32 cell survival in the presence of different cell
populations of PBMC (effector cells) was measured with and
without the addition of antibody (CE7y2a) in a 6 h assay.
The number of IMR-32 target cells addedper well was 2,500.
Figure 2 summarises the results obtained with mononuclear
cells, purified monocytes and nonadherent cells as effectors at
E/T ratios of 40:1 and 80:1. With the addition of CE7-y2a
antibodies, target cell death was slightly but not significantly
increased.
=A-448 C.H. D'USCIO et al.
Mononuclear cells
Discussion
In the present study, we analysed anti-neuroblastoma
cytolytic effector cells in ADCC assays with CE7yl, y2a and
y2b isotype-switch variants, using IMR-32 cells as a target.
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Figure 2 Time-dependent lysis of IMR-32 target cells in the
presence of human mononuclear cells, monocytes and nylon-
nonadherent lymphocytes. 51Cr-labelled IMR-32 (2,500 cells/well)
were incubated with and without CE7y2a (500 ng/well). Effector
cells were added at an E/T ratio of 40:1 (0-0) or 80:1
(U-U). Control without CE7y2a E/T 40:1 (0-0) and 80:1
(0-0). The dotted line refers to antibody-coated target cells in
the absence of effector cells (figure at top). Data represent the
mean of triplicate.
In contrast to the above, IMR-32 cell survival was distinct-
ly different in the presences ofmacrophages (Figure 3). In the
absence ofantibody, the rate ofdeath was very low. With the
addition of antibody, target cell killing was markedly in-
creased. The E/T ratios used were 20:1 and 5:1. Pre-exposure
of macrophages to rIFN-y increased both non-specific and
specific (antibody-mediated) killing. A post-lysis uptake of
5"Cr by macrophages from the supernatant could be excluded
(not shown).
ADCC activity ofdifferent CE7 isotypes
Lysis of IRM-32 cells by macrophages or by activated
macrophages was determined in the presence of CE7 1,
CE7y2a or CE7y2b antibodies, or of a 72a control anti-
arsonate antibody. Figure 4 shows the results of an experi-
ment with an E/T ratio of five and an incubation time of
10 h. Both normal and activated macrophages mediated cell
lysis in the presence of CE7y2a antibodies; neither anti-
arsonate at 40pgml-', nor any of the other CE7 antibodies
showed an effect. Similar results were obtained with other
E/T ratios and for other incubation periods, suggesting that
macrophage ADCC of the IMR-32 via the CE7 antigen is
mediated by the IgG2a isotype exclusively.
time [hi
Figure 3 Time-dependent lysis of IMR-32 target cells by human
macrophages and rIFN-y treated macrophages in the presence or
absence of CE7y2a (500 ng well). E/T ratio of 5:1 (0-0) or
20:1 (U--). Control without antibody E/T 5:1 (0-0) and
20:1 (0-0). The dotted line refers to antibody-coated target
without effector. The data represent the mean of triplicate.
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Figure 4 ADCC activities ofCE7yl, CE7y2a and CE7y2b and of
control IgG2a antibody. Antibody was added at various concen-
tration of 5'Cr-labelled IMR-32. Macrophages and IFNy activat-
ed macrophages at a E/T ratio of 5:1 and antibodies were added.
CE7y2a (M-*) control y2a (0-0), CE7y2b (0-0), CE771
(A-A. The results are compared to antibody coated IMR-32
cells without effector cells (0-0). Target cell lysis was assessed
after lOh.
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Such variants display identical binding characteristics,
because they contain the same H chain VDJ and L chain VJ
regions attached to different isotypes. Accordingly, different
effector functions can be clearly related to the respective
isotype, not influenced by differences in antibody affinity and
epitope binding. IMR-32 was found to be best suited for this
purpose since it showed lowest spontaneous lysis. When
measuring cytolysis in a 5"Cr release assay, it was found that
different effector cells exerted a significant degree of non-
specific activity; these cells were nylon-nonadherent lym-
phocytes (most probably NK/K cells) and elutriation-purified
monocytes. The presence of 'naturally' cytotoxic cells in the
monocyte fraction (up to 99% monocytes) was unexpected. If
endotoxins were not rigorously excluded, freshly isolated
monocytes were found to be cytotoxic in other systems
(Ziegler-Heitbrock et al., 1986). During elutriation, mono-
cytes were exposed to amounts of endotoxin sufficient to
induce the secretion of TNF-m. Because the sensitivity of our
target cells for TNF-x has not been established, TNF-ac must
be considered as one possible explanation for the observed
non-specific lysis. In contrast to the freshly isolated effector
cells, monocyte-derived macrophages cultured in vitro did not
display non-specific lysis.
Macrophage-mediated lysis of IMR-32 targets occurred
only with the addition of CE7'y2a antibodies. RIFN-' treated
macrophages enhanced the CE7y2a-dependent killing of
neuroblastoma cells. The 1l and 'y2b isotypes of CE7 did not
mediate ADCC. Specificity of cytolytic activity was demon-
strated with the addition of an irrelevant y2a antibody.
Recently, knowledge on human monocyte FcyR has pro-
gressed rapidly (Hogg, 1988) and up to now, three types of
FcRy have been found on peripheral blood leukocytes. They
are referred to as FcR7yI/CD64, FcR'yII/CD32 and FcRTyIII/
CD16, respectively. These FcR are distinguished antigenic-
ally, structurally, by isotype binding specificity and by bind-
ing affinity (Anderson & Looney, 1986; Fanger et al., 1989).
FcRyI, being mainly expressed on cells of the monocyte-
macrophage lineage, is unique in that it binds monomeric
human IgGl and IgG3, and murine IgG2a and IgG3. It
could therefore be involved in the CE7-y2a-mediated lysis of
IMR-32 cells. This is consistent with the findings of Steplew-
ski et al (1983) who demonstrated lysis of human colon
carcinoma cells by IgG2a-armed monocytoid effectors.
In a study similar to ours, IgG2b was also active in
mediating ADCC, although to a lower degree, than IgG2a
(Kipps et al., 1985). In their study, unseparated mononuclear
cells served as effector cells. Their effector cell preparation
contained cells of the NK/K lineage which express the low
affinity FcR^yIII. Thus, so far the consensus is that 72a is the
most effective murine isotype mediating ADCC regardless of
the effector cell involved. The hypothesis that FcR'yI mediates
lysis of CE7y2a-covered targets could be proven by the use of
blocking antibodies specific for FcR'?I; these antibodies were
unavailable at the time of this study. In the present study,
exposure of macrophages to rIFN-y, known to upregulate
selectively FcR'yI/CD64 (Jungi & Peterhans, 1988), promoted
enhanced CE7y2a-mediated lysis (Figure 3).
The antibody CE7, which is one of the few neuroblastoma
selective monoclonal antibodies but possesses some unique
features (Momoi et al., 1980; Reynolds & Smith, 1982;
Cheung et al., 1985; Sch6nmann et al., 1986), has been used
hitherto for diagnostic purposes. For therapeutic use an anti-
body should not only be specific, but also should mediate
appropriate effector functions, such as activation of the com-
plement system and the induction of ADCC. The present
study demonstrates that the strategy of selecting isotype
switch variants can fulfill these requirements. The y2a variant
of CE7 described here mediates both ADCC and comple-
ment fixation while the original 71 isotype is deficient in both
respects.
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